Search company, investor...
Forma Therapeutics company logo

Forma Therapeutics

formatherapeutics.com

Founded Year

2007

Stage

Acq - Pending | Acquired

Total Raised

$129.5M

Valuation

$0000 

About Forma Therapeutics

Forma Therapeutics (NASDAQ: FMTX) is a clinical-stage biopharmaceutical company. It focuses on the research, development, and commercialization of therapeutics to transform the lives of patients with rare hematologic diseases and cancers. The company was founded in 2007 and is based in Watertown, Massachusetts.

Headquarters Location

300 North Beacon Street Suite 501

Watertown, Massachusetts, 02472,

United States

617-679-1970

Missing: Forma Therapeutics's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Forma Therapeutics's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Forma Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Forma Therapeutics is included in 2 Expert Collections, including Cancer.

C

Cancer

4,784 items

Pharmaceutical and biotechnology companies with cancer therapy drug candidates.

B

Biopharma Tech

838 items

Forma Therapeutics Patents

Forma Therapeutics has filed 1 patent.

The 3 most popular patent topics include:

  • Transcription factors
  • Proteins
  • Clusters of differentiation
patents chart

Application Date

Grant Date

Title

Related Topics

Status

11/23/2020

11/15/2022

Transcription factors, Metabolism, EC 1.1.1, Cellular respiration, Trifluoromethyl compounds

Grant

Application Date

11/23/2020

Grant Date

11/15/2022

Title

Related Topics

Transcription factors, Metabolism, EC 1.1.1, Cellular respiration, Trifluoromethyl compounds

Status

Grant

Latest Forma Therapeutics News

CTOS 2022 Annual Meeting: A Phase 1/2 Study of CFT8634 Trial-in-Progress Poster

Nov 18, 2022

11/18/2022 | 09:29am EST Message : Degrader Of BRD9, in Synovial Sarcoma and SMARCB1-null Tumors Brian A. Van Tine, MD, PhD1, William D. Tap, MD2, Ravin Ratan, MD, M.Ed3, Steven Attia, D.O.4, Anthony Elias, MD5, Varun Monga, MD6, Lee P. Hartner, MD7, Mark Agulnik, MD8, Gary K. Schwartz, MD9, Amro Ali, PharmD10, Ingrid Mintautas, BA10, Riadh Lobbardi, PhD10, Oliver Schoenborn-Kellenberger, MSc10, Eunju Hurh, PhD10, Kathleen Neville, MD10, and Gregory M. Cote, MD, PhD11 1Washington University School of Medicine, St. Louis, MO; 2Memorial Sloan Kettering Cancer Center, New York, NY; 3University of Texas MD Anderson Cancer Center, Houston, TX; 4Division of Oncology, Mayo Clinic, Jacksonville, FL; 5University of Colorado Cancer Center, Aurora, CO; 6University of Iowa Hospitals and Clinics, Iowa City, IA; 7Abramson Cancer Center, University of Pennsylvania, Philadelphia, PA; 8City of Hope, Duarte, CA; 9Columbia University Herbert Irving Comprehensive Cancer Center, New York, NY; 10C4 Therapeutics, Inc., Watertown, MA; 11Massachusetts General Hospital Cancer Center, Boston, MA BACKGROUND Two types of genetic alterations disturb SMARCB1: SS18-SSX gene fusion and SMARCB1 loss-of-function(SMARCB1-null) The presence of SS18-SSX chromosomal translocation drives the development of synovial sarcoma (SS), a soft tissue malignancy comprising ~10% of all soft tissue sarcomas2 • SMARCB1-null tumor types include malignant rhabdoid tumor (MRT), poorly Figure 1: Oncogenic SS18-SSX Fusion Leads to BRD9 Dependency PRE-CLINICAL DATA: IN VIVO IN PDX Figure 5: Robust Efficacy Response Observed in Two PDX Models of Synovial Sarcoma A. PDX SA13412 in situ hybridization, or other equivalent tests like gene mutation analysis, KEY EXCLUSION CRITERIA in Synovial Sarcoma1 poor with limited therapeutic options (e.g., synovial sarcoma: 1-year survival rate ~60%)4 cBAF ARID1A/B SSX • • confer clinical benefit and must be ≥18 years of age, or ≥16 years old and weigh ≥50 kg planned first dose of CFT8634 • Patient should not have received another BRD9 degrader C1 **Compromised****Aberrant** CFT8634 1 mg/kg (PO QD) CFT8634 30 mg/kg (PO QD) CFT8634 3 mg/kg (PO QD) CFT8634 50 mg/kg (PO QD) Vehicle 24 h post-Day 18 dose 0 CFT8634 1 mg/kg (PO QD) CFT8634 30 mg/kg (PO QD) CFT8634 3 mg/kg (PO QD) CFT8634 50 mg/kg (PO QD) STUDY ENDPOINTS7 Figure 2: Mechanism of Action for CFT86346 the DUF domain is critical, while a degrader approach achieves efficacy2 Figure 6: Durable Response Observed in a PDX Model of Synovial Sarcoma PRIMARY ENDPOINT • CFT8634 is an orally bioavailable selective bifunctional degradation activating compound, or BiDAC™ degrader, of BRD9 CFT8634 was synthesized using C4 Therapeutics' TORPEDO® platform Mechanism of action (Figure 2) CFT8634 induces a ternary complex formation with BRD9 and cereblon E3 ligase (step 1) BRD9 is ubiquitinated and subsequently degraded by the proteasome (steps 2-4) CFT8634 is highly selective for BRD9 and demonstrates dose proportional exposure in both plasma and cell-derived xenograft models (Figures 3-4) CFT8634 leads to robust and dose-dependent degradation of BRD9, which translated to significant and dose-dependentanti-tumor activity in preclinical in vitro and in vivo models of SMARCB1-perturbed cancers (Figures 5-6) PRE-CLINICAL DATA: IN VITRO Durable Tumor Regression in PDX SA134126 Drug treatment period Tumor regressions were durable with no regrowth observed These pre-clinical results provide the rationale for a Phase 1 study (first-in-human) to evaluate CFT8634 in synovial sarcoma and SMARCB1-null tumors • • • STUDY STATUS/ENROLLMENT OR • B. HSSYII cell line • • Dose escalation phase, beginning with a starting oral dose of 2 mg daily, will follow a Bayesian logistic regression model until determination of the MTD and/or RP2D • Escalation will include synovial sarcoma and SMARCB1 deleted solid tumors (N = ~40) • CA SECONDARY ENDPOINTS ORR (Phase 1) Figure 4: Dose Proportional Exposure and Concordant Cross-Species PK Profile in a Cell-Derived Xenograft (Yamato-SS) A. Plasma PK6 CFT8634 1 mg/kg (PO QD) CFT8634 3 mg/kg (PO QD) CFT8634 10 mg/kg (PO QD) 1 CFT8634 50 mg/kg (PO QD) 0 4 • Figure 7: CFT8634 Study Design Phase 1 Escalation (Illustrative) SS† CFT8634 CFT8634 N = ~20 *CFT8634 is administered in 28-day cycles until disease progression or intolerable toxicity. † Once the RP2D has been declared, expansion arms for synovial sarcoma and SMARCB1-null tumors will begin enrollment. Abbreviations AE, adverse event; BID, twice daily; BRD4, bromodomain containing 4; BRD7, bromodomain containing 7; BRD9, bromodomain containing 9; cBAF, canonical BAF; CDX, cell line-derivedxenograft; CRBN, cereblon; DoR, duration of response; DLT, dose limiting toxicities; ECG, electrocardiogram; HiBiT, high affinity bioluminescent tag; MTD, maximum tolerated dose; ncBAF, noncanonical BAF; ORR, overall response rate; OS, overall survival; pBAF, polybromoBAF; PD, pharmacodynamics; PDX, patient-derivedxenografts; PFS, progression free survival; PK, pharmacokinetics; PO, by mouth; QD, once daily; RP2D, recommended phase 2 dose; SAE, serious adverse event; SMARCB1, SWI/SNF-related matrix-associated actin-dependentregulator of chromatin subfamily B member 1; SS, synovial sarcoma; TID, thrice daily Disclosures BVT: leadership: Polaris; honoraria: Bionest Partners, Horizon CME, Research to Practice, Targeted Oncology; consulting or advisory role: Adaptimmune, ADRx, Apexigen, Ayala Pharmaceuticals, Bayer, Cytokinetics, Daiichi Sankyo, Deciphera, EMD Serono, Epizyme, GlaxoSmithKline, Immune Design, IntelliSphere, Lilly, Novartis, Pfizer; speakers' bureau at Adaptimmune, GlaxoSmithKline, Lilly, Novartis; research funding: GlaxoSmithKline, Merck, Pfizer, TRACON Pharma; patents, royalties, other intellectual property: Accuronix Therapeutics - Licensing agreement, Sigma-2 Receptor Ligands and Therapeutic uses therefor (006766), Modular Platform for Targeted Therapeutic Delivery (006755), Sigma-2 Receptor Ligand Drug Conjugates as Antitumor Compounds, Methods of synth; patent on ALEXT3102; patent on the use of ME1 as a biomarker; expert testimony: Health Advances; travel, accommodations, expenses: Adaptimmune, Advenchen Laboratories, GlaxoSmithKline, Lilly. WT: research funding: AmMax Bio, Atropos Therapeutics, Ayala Pharmaceuticals, Bayer, Certis Oncology Solutions, Cogent Biosciences, Connecting Humans in Health, Daiichi Sankyo, Deciphera, Eli Lilly, Epizyme, Foghorn Therapeutics, Kowa Research Institute, MedPacto, Novo Holdings A/S. RR: stock and other ownership interests: Johnson & Johnson, Medtronic; honoraria: touchIME; consulting or advisory role: Epizyme; research funding: Ayala Pharmaceuticals, Bayer, Epizyme, SpringWorks Therapeutics; travel, accommodations, expenses: SpringWorks Therapeutics. SA: research funding: Desmoid Tumor Research Foundation, AB Science, TRACON Pharma, Bayer, Novartis, Lilly, Karyopharm Therapeutics, Epizyme, Blueprint Medicines, Genmab, CBA Pharma, Merck, Philogen, Gradalis, Deciphera, Takeda, Incyte, SpringWorks, Adaptimmune, Advenchen Laboratories, Bavarian Nordic, BTG, PTC Therapeutics, GlaxoSmithKline, FORMA Therapeutics, TRACON Pharma, Ayala Pharmaceuticals, Trillium Therapeutics, Boehringer Ingelheim, Salarius Pharmaceuticals, Theseus Pharmaceuticals, Monopar Therapeutics, C4 Therapeutics, Inhibrx, Noxopharm and Rain Therapeutics. AE: no disclosures. VM: research funding: Amgen, Forma Therapeutics, GSK, Deciphera, Trillium, Astex Pharma, Prelude Therapeutics, Pfizer, Oblato, Hutchison; advisory role: Forma Therapeutics and Astex Pharmaceuticals. LH: no disclosures. MA: consulting or advisory role: Lilly, Adaptimmune, Regeneron, AstraZeneca, BMS, Bayer, Deciphera; research funding: Exelixis. GS: stock and other ownership interests: GenCirq, Bionauts Labs, January Therapeutics; consulting or advisory role: Bionaut Labs, Ellipses Pharma, GenCirq, Epizyme, Array BioPharma, Apexigen, Oncogenuity, OnCusp, Concarlo, Shanghai Pharma, Astex, January Therapeutics, Sellas Life Sciences, Purtech, Killys Therapeutics; research funding: Astex Pharmaceuticals, Incyte, Calithera Biosciences, Lilly, Daiichi Sankyo, Fortress, Karyopharm Therapeutics, Oxford BioTherapeutics, Astex Pharmaceuticals, TopAlliance BioSciences, Adaptimmune, SpringWorks Therapeutics, TRACON Pharma; travel, accommodations, expenses: Array Biopharma and Epizyme. AA: employed by and equity holder in C4 Therapeutics. IM: employed by and equity holder in C4 Therapeutics. RL: employed by and equity holder in C4 Therapeutics. OSK: consultancy at C4 Therapeutics. EH: employed by and equity holder in C4 Therapeutics. KN: employed by and equity holder in C4 Therapeutics. GC: research funding: Servier Pharmaceuticals, Epizyme, PharmaMar, MacroGenics, Eisai, Merck, Bavarian Nordic, Bayer, SpringWorks Therapeutics, Repare Therapeutics, Foghorn Therapeutics, SMP Oncology, Jazz Pharmaceuticals, RAIN Therapeutics, BioAtla, InhibitRX, Ikena, C4 Therapeutics. References Copies of this poster 1. Jackson KL, et al. AACR 2022. Oral Presentation. 2. Brien GL et al. eLife. 2018;7:e41305. 3. Sergi CM. Biosci Rep. 2022;42(6):BSR20220040. 4. Aytekin MN. J Orthop Surg. obtained through 2020;28(2):2309499020936009. 5. Michel BC, et al. Nat Cell Biol. 2018;20(12):1410-1420.6. C4 Therapeutics data on file. 7. NCT05355753. www.clinicaltrials.gov. Accessed QR Code are for personal September 9, 2022.

Forma Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Forma Therapeutics Rank

Forma Therapeutics Frequently Asked Questions (FAQ)

  • When was Forma Therapeutics founded?

    Forma Therapeutics was founded in 2007.

  • Where is Forma Therapeutics's headquarters?

    Forma Therapeutics's headquarters is located at 300 North Beacon Street, Watertown.

  • What is Forma Therapeutics's latest funding round?

    Forma Therapeutics's latest funding round is Acq - Pending.

  • How much did Forma Therapeutics raise?

    Forma Therapeutics raised a total of $129.5M.

  • Who are the investors of Forma Therapeutics?

    Investors of Forma Therapeutics include Novo Nordisk, Wellington Management, RA Capital Management, Samsara BioCapital, Cormorant Asset Management and 9 more.

  • Who are Forma Therapeutics's competitors?

    Competitors of Forma Therapeutics include CellCentric, Cognition Therapeutics, Five Prime Therapeutics, Nuevolution, Prosarix and 11 more.

Compare Forma Therapeutics to Competitors

CellCentric Logo
CellCentric

CellCentric is a clinical stage biotechnology company focused on the development of the novel drug CCS1477 for prostate (CRPC) and other cancers.

I
IITRI Drug Discovery Division

IIT Research Institute (IITRI) is a contract research organization (CRO) that aims to provide non-clinical toxicology and other drug development services to government and industry. IITRI offers particular expertise in oncologics drug development, inhalation toxicology and technology, carcinogenesis and cancer prevention, and biodefense. IITRI's Drug Discovery Division is a research-based group whose focus is the design and synthesis of new small molecule therapeutics for cancer and infectious disease.

W
Welichem Biotech

Welichem Biotech Inc. ("Welichem", TSX-V: WBI) is engaged in the discovery and development of small molecule therapeutics. Using its Symbiochem technology platform, the Company has developed a robust pipeline of patent-protected compounds that target autoimmune/inflammatory diseases and cancers. Welichem's lead drug candidate, WBI-1001, targets autoimmune/inflammatory skin disorders, such as psoriasis and eczema. A phase I clinical trial of WBI-1001, done in Montreal, in patients with psoriasis has shown a very good safety profile and promising efficacy. As well, the application of WBI-1001 cream against atopic dermatitis (a type of eczema) in a phase IIa clinical trial also has been completed in Canada, with the final report pending in the third quarter of 2008. Welichem plans to all the necessary Phase II Clinical Trials against psoriasis and eczema in the near future. In the company's pipeline, WBI-1001 related compounds are being evaluated also for their therapeutic potential against other autoimmune diseases such as, inflammatory bowel disease and rheumatoid arthritis. Welichem's other lead drug candidate, WBI-2100, selectively targets certain types of hard-to-treat cancerous tumours. This is achieved in part through inhibition of angiogenesis and metastasis. Animal tests have shown that WBI-2100 is effective as a monotherapy and also in increasing the effectiveness of several commonly used chemotherapeutic products. The uniqueness of this small molecule cancer chemotherapeutic is that in pre-clinical studies it increases the number of neutrophils in the peripheral blood. The boosting of neutrophils in animal studies in the presence of the cancer therapeutic, cyclophosphamide, supports its potential therapeutic application for chemotherapy induced neutropenia. With its proven Symbiochem; technology platform, Welichem will advance its pipeline of drug candidates at a rate and time commensurate with resources and target need, and is in a strong position to contribute effectively to productive drug discovery and development partnerships.

P
Priaxon

Priaxon is a research company focusing on drug discovery for small molecule therapeutics.

I
InVasc Therapeutics

InVasc Therapeutics specializes in target-specific drug discovery and has developed a approach to drug discovery that uses molecular structures and an application-based platform that decreases the time and expense of current large-scale "mining"� discovery techniques. The InVasc process is the result of university-based research at Emory University and The Ohio State University.

S
Syntopix

Syntopix is a specialised research and development business, focusing on the discovery of topical antimicrobials for healthcare and pharmaceutical applications through the repositioning of known chemical entities that have a history of use in humans.nThe company seek to identify compounds and develop products that treat dermatological conditions, principally acne and topical staphylococcal infections, including those due to MRSA.nThe company's antimicrobial expertise is now also being successfully applied to other areas as the company develop collaborative relationships with major healthcare companies.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.